Jin-Gui-Shen-Qi Wan ameliorates diabetic retinopathy by inhibiting apoptosis of retinal ganglion cells through the Akt/HIF-1α pathway

作者全名："Liang, Dan; Qi, Yulin; Liu, Lu; Chen, Zhaoxia; Tang, Shiyun; Tang, Jianyuan; Chen, Nianzhi"

作者地址："[Liang, Dan; Tang, Jianyuan] Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Peoples R China; [Qi, Yulin] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou, Peoples R China; [Liu, Lu] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Peoples R China; [Chen, Zhaoxia; Tang, Shiyun] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China; [Chen, Nianzhi] Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing, Peoples R China"

通信作者："Tang, JY (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Peoples R China.; Tang, SY (通讯作者)，Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.; Chen, NZ (通讯作者)，Chongqing Med Univ, Coll Biomed Engn, State Key Lab Ultrasound Med & Engn, Chongqing, Peoples R China."

来源：CHINESE MEDICINE

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001086865900002

JCR分区：Q1

影响因子：5.3

年份：2023

卷号：18

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：JGSQ; Diabetic retinopathy; Akt/HIF-1 alpha pathway; Retinal ganglion cells

摘要："Background Jin-Gui-Shen-Qi Wan (JGSQ) has been used in China for thousands of years to treat various ailments, including frequent urination, blurred vision, and soreness in the waist and knees. It has traditional therapeutic advantages in improving eye diseases.Aim of the study Clinical studies have confirmed the therapeutic efficacy of JGSQ in improving diabetes and vision; however, its efficacy and pharmacological effects in treating diabetic retinopathy (DR) remain unclear. Therefore, the aim of this study was to investigate the specific pharmacological effects and potential mechanisms of JGSQ in improving DR through a db/db model.Materials and methods db/db mice were given three different doses of orally administered JGSQ and metformin for 8 weeks, and then PAS staining of the retinal vascular network patch, transmission electron microscopy, H&E staining, and TUNEL staining were performed to determine the potential role of JGSQ in improving DR-induced neuronal cell apoptosis. Furthermore, network pharmacology analysis and molecular docking were carried out to identify the main potential targets of JGSQ, and the efficacy of JGSQ in improving DR was evaluated through western blotting and immunofluorescence staining, revealing its mechanism of action.Results According to the results from H&E, TUNEL, and PAS staining of the retinal vascular network patch and transmission electron microscopy, JGSQ does not have an advantage in improving the abnormal morphology of vascular endothelial cells, but it has a significant effect on protecting retinal ganglion cells from apoptosis. Through network pharmacology and molecular docking, AKT, GAPDH, TNF, TP53, and IL-6 were identified as the main core targets of JGSQ. Subsequently, through western blot and immunofluorescence staining, it was found that JGSQ can inhibit HIF-1 alpha, promote p-AKT expression, and inhibit TP53 expression. At the same time, inhibiting the release of inflammatory factors protects retinal ganglion cells and improves apoptosis in DR.Conclusion These results indicated that in the db/db DR mouse model, JGSQ can inhibit the expression of inflammatory cytokines and protect retinal ganglion cells from apoptosis, possibly by modulating the Akt/HIF-1 alpha pathway."

基金机构：Not applicable.

基金资助正文：Not applicable.